Pear Therapeutics, Inc. (PEAR) is a publicly traded company in the Unknown sector. Across all available filings, 23 corporate insiders have executed 70 transactions totaling $5.8M, demonstrating a bearish sentiment with -$5.8M in net insider flow. The most recent transaction on Apr 10, 2023 involved a sale of 534,855 shares valued at $64.2K.
No significant insider buying has been recorded for PEAR in the recent period.
No significant insider selling has been recorded for PEAR in the recent period.
Based on recent SEC filings, insider sentiment for PEAR is bearish with an Insider Alignment Score of 0/100 and a net flow of -$5.8M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Pear Therapeutics, Inc. (PEAR) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 23 insiders are actively trading PEAR stock, having executed 70 transactions in the past 90 days. The most active insider is Andrew J. Schwab (Executive), who has made 10 transactions totaling $2.7M.
Get notified when executives and directors at PEAR file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Apr 10, 2023 | Iv, L.p. 5am Co-investors | Executive | Sale | 534,855 | $0.12 | $64.2K | |
| Apr 10, 2023 | Iv, L.p. 5am Co-investors | Executive | Sale | 3,172,769 | $0.12 | $380.7K | |
| Apr 10, 2023 | Iv, L.p. 5am Co-investors | Executive | Sale | 12,836,489 | $0.12 | $1.5M | Large |
| Feb 15, 2023 | Bauerlein Alison | Executive | Award | 71,428 | $N/A | $0 | |
| Feb 15, 2023 | Mango Paul | Executive | Award | 52,380 | $N/A | $0 | |
| Feb 15, 2023 | Rajaraman Shivakumar | Executive | Award | 52,380 | $N/A | $0 | |
| Feb 15, 2023 | Reddy Kirthiga | Executive | Award | 61,904 | $N/A | $0 | |
| Feb 15, 2023 | M. Schlichting Nancy | Executive | Award | 66,666 | $N/A | $0 | |
| Feb 15, 2023 | A. Wicks Timothy | Executive | Award | 52,380 | $N/A | $0 | |
| Jan 20, 2023 | Jeffery Katherine | Executive | Sale | 7,096 | $1.13 | $8.0K | |
| Jan 20, 2023 | Mccann Corey | Executive | Sale | 34,731 | $1.13 | $39.2K | |
| Jan 20, 2023 | Maricich Yuri | Executive | Sale | 12,162 | $1.13 | $13.7K | |
| Jan 20, 2023 | T. Guiffre Christopherd | Executive | Sale | 19,540 | $1.13 | $22.1K | |
| Jan 20, 2023 | Snow Ellen | Executive | Sale | 8,027 | $1.13 | $9.1K | |
| Jan 20, 2023 | K. Brenner Erin | Executive | Sale | 8,690 | $1.13 | $9.8K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 41 | $5.8M | 73.3% |
Award(A) | 17 | $2.1M | 26.3% |
Exercise(M) | 10 | $30.0K | 0.4% |
Other(J) | 1 | $0 | 0.0% |
Conversion(C) | 1 | $0 | 0.0% |
Insider selling pressure at Pear Therapeutics, Inc. has increased, with 23 insiders executing 70 transactions across all time. Total sales of $5.8M significantly outpace purchases of $0, resulting in a net outflow of $5.8M. This selling activity appears largely discretionary, which may warrant closer attention from investors.